Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1101-1120 of 1,738 trials

Advanced Melanoma: Enfortumab Vedotin with Pembrolizumab

We are studying a combination of two treatments for patients with advanced melanoma who have been previously treated. The goal is to see if this combination is effective and safe for improving patient outcomes.

Metastatic MelanomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Solid Tumors: Long-Term Safety of Brigimadlin

We are studying the long-term effects of brigimadlin in people with solid tumors who have previously taken this medication. The goal is to understand how well they tolerate it and any side effects that may occur.

Solid TumoursEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Dent 2 Disease: Alpelisib Study

We are testing the medication alpelisib in patients with Dent 2 disease to see if it improves kidney function and is safe to use. This study will help us understand its potential benefits for kidney health.

Dent's DiseaseEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrologyUrology

Navepegritide for Growth in Adolescents with Achondroplasia

We are studying whether navepegritide can help improve growth in adolescents aged 12 to under 18 with achondroplasia. This trial will help us understand its effectiveness and safety.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

Malignant Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced NSCLC: NVL-655 Treatment Study

We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK MutationSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Esophageal Cancer: Ifinatamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for people with untreated advanced esophageal cancer. The goal is to see if it is safe and effective compared to standard options.

Esophageal Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesOncology

Headache Relief: Sphenopalatine Block for Subarachnoid Hemorrhage

We are studying whether a nerve block can help reduce headaches and the need for pain medication in patients with non-traumatic subarachnoid hemorrhage. This trial also looks at patient satisfaction and potential complications.

Subarachnoid Hemorrhage>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Pulmonary Hypertension: TX000045 Treatment Study

We are testing a new medication, TX000045, for patients with pulmonary hypertension due to heart failure. The goal is to see if it improves heart function and is safe for use.

Pulmonary Hypertension3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: Gemcitabine vs. Reduced-Dose Chemotherapy

We are studying whether standard-dose gemcitabine or a reduced-dose combination chemotherapy is more effective for fragile patients with non-resectable pancreatic cancer. This research aims to find the best treatment for those who cannot tolerate full-dose chemotherapy.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

FAPI PET Imaging for Pleural Mesothelioma

We are studying how effective FAPI PET scans are for diagnosing and staging pleural mesothelioma. This research may help improve treatment decisions and monitoring for patients with this condition.

Pleural Mesothelioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngology

Vaginal Atrophy: New Estriol Vaginal Ring

We are testing a new vaginal ring that releases estriol to see if it improves vaginal health in postmenopausal women. The study will measure changes in vaginal tissue and pH after treatment.

Vulvovaginal Atrophy≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Propofol Injection Pain Study

We are investigating whether propofol causes more pain than a placebo in healthy adults. This study aims to better understand pain levels during and after the injection.

Pain Relief1-2 yearsEfficacy phase (II)Standard MedicinesInternal MedicineOtolaryngologyPsychiatry

Trabectedin for HEY1-NOCA2 Positive Mesenchymal Chondrosarcoma

We are studying the effects of trabectedin in adults and young adults with advanced mesenchymal chondrosarcoma who have already received other treatments. The trial aims to assess how well this medication works in reducing tumors and improving patient outcomes.

Mesenchymal Chondrosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Preventing Chemotherapy-Induced Nausea in Children: IV NEPA Study

We are studying a new intravenous treatment for children with cancer to see if it can effectively prevent nausea and vomiting during chemotherapy. This trial compares IV NEPA with standard treatments to ensure safety and effectiveness.

Chemotherapy-Induced Nausea and Vomiting3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncologyPediatrics

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Pseudomyxoma Peritonei: Neoadjuvant Chemotherapy Study

We are studying whether a combination of capecitabine and cyclophosphamide can help patients with large Pseudomyxoma peritonei before surgery. The goal is to see if this treatment improves tumor shrinkage and surgical success.

Pseudomyxoma Peritonei>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

PRCA Treatment: Isatuximab Study

We are studying whether the drug isatuximab can help patients with pure red cell aplasia after stem cell transplantation. This trial compares its effects to standard supportive care to see which is more effective.

Pure Red Cell Aplasia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology